NCT03022682Recruiting
Inflammation, Diabetes, Ethnicity and Obesity Cohort
Development of a Multi-Ethnic, Multimodal Obesity Cohort
Source: ClinicalTrials.gov · Last updated 8 Sept 2026
Brief summary (registry, in English)
Obesity affects over one third of US adults (\>72 million, with BMI ≥30 kg/m2), and the proportion of US adults with BMI ≥40 kg/m2 has doubled in the last 20 years. Obesity is associated with increased mortality through its linkage to comorbidities including diabetes, hypertension, dyslipidemia, osteoarthritis, sleep apnea and psychosocial disturbances. Given its prevalence, impact on morbidity and mortality, and economic cost, limiting the spread of obesity and its consequences is one of the most important problems of our time. In this proposed study, investigators will recruit participants from a wide range of body mass index (BMI), ethnicity and Diabetes risk to collect data and blood, stool and adipose tissue samples in the San Francisco bay area.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 350 (estimated)
- First submitted
- 12 Jan 2017
- Start date
- 1 Feb 2015
- Primary completion date
- 31 Dec 2029
- Lead sponsor
- University of California, San Francisco
- Diseases
- Obesity
- NCT number
- NCT03022682
What you commit to
- Study type: Observational
- Planned participants: 350
- From 1 Feb 2015 to the primary completion date, 31 Dec 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treatment with chemotherapy or radiation therapy at the time of enrollment in study.
- Current nasal corticosteroid use (within the past month)
- Current use of anabolic steroids or testosterone for bodybuilding purposes. Testosterone use is permitted if prescribed for hypogonadism and dose stable for the past 6 months.
- Patients actively enrolled in interventional trials involving investigational agents
- Previous bariatric surgery
- Methadone medication
Other illness
- Participants with chronic kidney disease (\> stage 4)
- Autoimmune/inflammatory disease (e.g., Lupus, Ulcerative Colitis, etc.)
- Unstable angina, New York (NY) class III or IV congestive heart failure or myocardial infarction within 3 months of entry
- Clinically significant liver disease (e.g. Cirrhosis or liver failure)
- History of organ transplant
- History of abnormal clotting
Other
- Weight \> 450 pounds (DXA scan weight limit)
- Poorly controlled asthma (participants requiring inhaled glucocorticoids and/or oral glucocorticoids)
- Excessive alcohol or substance abuse
- Pregnant or breast-feeding women
- Appears unlikely or unable to participate in the required study procedures as assessed by the investigator, study coordinator or designee.
- Anticoagulant use
Who the study is looking for
- Participants will be healthy individuals between the ages of 18-75 years. These cutoffs are designed to allow inclusion of postmenopausal women, and younger/more active patients who are increasingly undergoing bariatric surgery.
- Patients with either diabetes type 2 or the metabolic syndrome will be included in the cohort.
Age in the registry: 18 years to 75 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of California San Francisco Coordinator of this site? Confirm its status | San Francisco | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.